Charles River price target raised to $200 from $190 at Evercore ISI

Evercore ISI analyst Elizabeth Anderson raised the firm’s price target on Charles River (CRL) to $200 from $190 and keeps an Outperform rating on the shares. The firm’s survey work points to a positive outlook for preclinical CROs, with rising budgets and declining cancellations, along with suggesting stable demand for discovery and toxicology services into 2025 and 2026, the analyst tells investors in a note on the group.

Elevate Your Investing Strategy:

Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on CRL:

Disclaimer & DisclosureReport an Issue

Nike upgraded, RH downgraded: Wall Street’s top analyst calls Charles River upgraded to Overweight from Equal Weight at Barclays Charles River Labs: Navigating Leadership Changes and Market Challenges with a Hold Rating Hold Rating on Charles River Labs Amid Leadership Transition and Market Uncertainty Trump announces $15B libel suit against New York Times: Morning Buzz

View comments